Open Access

Erratum to: PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer

  • Gordon C Wishart1, 7Email author,
  • Elizabeth M Azzato2, 3,
  • David C Greenberg4,
  • Jem Rashbass4,
  • Olive Kearins5,
  • Gill Lawrence5,
  • Carlos Caldas1, 6, 7 and
  • Paul DP Pharoah2
Breast Cancer Research201012:401

DOI: 10.1186/bcr2480

Published: 1 March 2010

The original article was published in Breast Cancer Research 2010 12:R1

Following the publication of our article [1] we noticed an error in Table 1 relating to the number of patients who received adjuvant therapy. The correct table is given here (Table 1).
Table 1

Patient characteristics for model development (ECRIC) and validation (WMCIU) cohorts

 

ECRIC

 

WMCIU

 

Total Number of Subjects

5,694

 

5,468

 

Total time at risk (years)

31,904

 

25,917

 

Median follow-up (years)*

5.65

(0.04-8.00)

4.85

(0.07-8.00)

Number of breast cancer deaths

737

 

668

 

Number of other deaths

338

 

287

 

Annual breast cancer mortality rate

0.023

(0.021-0.025)

0.026

(0.024-0.028)

5-year breast cancer survival rate

0.89

(0.88-0.90)

0.88

(0.87-0.89)

Median age at diagnosis, years

58

(23-95)

58

(22-93)

 

Number

%

Number

%

Age, years

    

   <35

111

2

108

2

   35-49

1,172

21

1,195

22

   50-64

2,630

46

2,393

44

   65-74

1,124

20

1,101

20

   75+

657

12

671

12

Nodal status

    

   0

3,532

62

3,184

58

   1

741

13

746

14

   2-4

806

14

792

14

   5-9

380

7

451

8

   10+

235

4

295

5

Tumour size, mm

    

   <10

625

11

485

9

   10-19

2,310

41

2,136

39

   20-29

1,627

29

1,566

29

   30-49

845

15

923

17

   50+

287

5

358

7

Grade

    

   I

1,005

18

1,017

19

   II

2,927

51

2,442

45

   III

1,762

31

2,009

37

ER Status

    

   ER negative

991

17

1,116

20

   ER positive

4,703

83

4,352

80

Adjuvant therapy

    

   None

643

11

1,520

28

   Chemotherapy only

783

14

1,542

28

   Endocrine therapy

3,146

55

1,827

33

   Combined chemoendocrine

1,122

20

579

11

Screen detected

    

   Yes

1,621

28

1,256

23

   No

4,073

72

4,212

77

*Follow-up censored at 8 years

Range of variable

95 CI

Notes

Authors’ Affiliations

(1)
Cambridge Breast Unit, Addenbrooke's Hospital
(2)
Strangeways Research Laboratory, Department of Oncology, University of Cambridge
(3)
Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute
(4)
Eastern Cancer Registration and Information Centre (ECRIC), Unit C, Magog Court
(5)
West Midlands Cancer Intelligence Unit, Public Health Building, The University of Birmingham
(6)
Department of Oncology, University of Cambridge, and Functional Breast Cancer Genomics Laboratory, Cancer Research UK Cambridge Research Institute, Li Ka-Shing Centre
(7)
National Institute of Health Research (NIHR) Cambridge Biomedical Research Centre, Addenbrooke's Hospital

References

  1. Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, Caldas C, Pharoah PD: PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 2010, 12: R1-10.1186/bcr2464.PubMedPubMed CentralView ArticleGoogle Scholar

Copyright

© BioMed Central Ltd 2010

Advertisement